Potential Utiliy of GATA3 and P63 Immunohistochemistry in Differentiating Urothelial Carcinoma from Prostate Adenocarcinoma
/ 0
- Details
- Category: Vol. 82, December 2014
- Hits: 1185
Potential Utiliy of GATA3 and P63 Immunohistochemistry in Differentiating Urothelial Carcinoma from Prostate Adenocarcinoma, AHLAM A. ABDELMAKSOUD and ADEL Z. ELSEAIDY
Abstract
Background: Prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder are common cancers in men. High grade forms of these tumors may present ambiguous morphologic features that make distinguishing invasive high-grade urothelial carcinoma (UC) from high-grade prostatic adenocarcinoma difficult. The distinction between the two tumors has significant staging and therapeutic implications. Hence, an accurate diagnosis is essential.
Aim: To compare the expression of GATA3 and p63 in urothelial carcinomas and adenocarcinomas of prostate.
Material and Methods: Immunohistochemistry (IHC) for GATA binding protein 3 (GATA3) and p63 was performed on a tissue sections of 30 cases of invasive high-grade UC and of 30 high-grade prostatic adenocarcinomas.
Results: GATA3 and p63 were positive in 25 (83.3%) and in 27 (90%) of high-grade UC, respectively. All GATA3 positive staining was diffuse, from which 22 (88%) cases demonstrated moderate-strong staining, and 3 (12%) cases demonstrated weak staining. Of the 5 cases that failed to express GATA3, 3 were positive for p63, while 2 cases were negative for both 2 markers. None of the prostatic adenocar-cinomas expressed either GATA3 or p63.
Conclusion: GATA3 and p63 IHC are sensitive markers for UC and can be used to distinguish prostatic adenocarci-nomas from urothelial carcinomas in difficult cases. They are also highly specific in excluding high-grade prostatic carcinoma.